Skip to main content

CAR T-Cell Clinical Trials

 
 

The Bone Marrow Transplantation & Cellular Therapy Department conducts CAR T-cell clinical trials for children and young adults with relapsed or refractive leukemia. These studies use chimeric antigen receptor (CAR) products developed and produced at the Children’s GMP, LLC, which is located on the St. Jude campus.

St. Jude Clinical Trials

 
 

CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

  • 21 years old or younger
  • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
  • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
View Trial

MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

  • At least 18 years old
  • At least single haplotype matched family member

Recipient eligibility includes:

  • 21 years old or younger*
  • Diagnosed with relapsed and/or refractory CD19-positive leukemia
  • Not suitable for autologous CD19-CAR T-cell therapy

* Initial 3 participants must be at least 16 years old.

View Trial

SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

 

 

View Trial
Close